Gop One Non Peptide Gop One Peptide in treating obesity

A study looked at the non-peptide GLP-1 receptor agonist Ofor Glibron in adults with obesity and comorbidities related to weight. The study showed significant weight loss ranging from 8% to 13%, with dose dependence and continuous weight loss throughout the 36-week trial. Cardiometabolic profiles also improved, with lower systolic blood pressure. Adverse events, mostly GI-related, occurred in 10-20% of participants, with symptoms diminishing over time. The study suggests that an oral GLP-1 agent could be a game-changer for weight loss if dosing and GI side effects are managed.